Figure 1.
Study design.
Figure 2.
CONSORT patient flowchart.
Table 1.
Demographic and baseline characteristics (ITT population).
Table 2.
Proportion of patients achieving initial and definitive cure after treatment with amphotericin B emulsion and liposomal amphotericin B (mITT population).
Figure 3.
Increase in Hb levels (A) and body weight (B) from baseline after treatment with lipid and liposomal formulations of amphotericin B (mITT population).
Table 3.
Summary of adverse events (AEs) and treatment-emergent adverse events (TEAEs) (ITT population).